Bristol Myers Squibb (BMS; NYSE: BMY) has expanded its 2016 partnership with IMIDomics, broadening the collaboration’s focus to include the collection of clinical and epidemiological data from patients with Sjögren’s disease and atopic dermatitis. This initiative aims to enhance the understanding of the underlying mechanisms of these immune-mediated inflammatory diseases (IMIDs). Initially, the partnership concentrated on conditions such as ulcerative colitis (UC), Crohn’s disease, psoriatic arthritis, rheumatoid arthritis (RA), psoriasis, and systemic lupus erythematosus (SLE).
The analysis of the newly gathered data is expected to help identify patient populations most likely to respond to treatments, thereby improving the chances of success in drug development. Financial terms of the expanded collaboration were not disclosed.- Flcube.com
